Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQO3J7
|
|||
| Drug Name |
NGR-TNF
|
|||
| Drug Type |
Fusion protein
|
|||
| Indication | Mesothelioma [ICD-11: 2C51.2; ICD-10: C45; ICD-9: 163] | Phase 3 | [1] | |
| Company |
AGC Biologics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01098266) NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.